The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Venetoclax-based salvage therapy in patients with R/R AML previously treated with targeted agents
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses findings from a retrospective analysis investigating the efficacy of venetoclax-based salvage therapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) previously treated with FLT3 or IDH inhibitors. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
